Danicopan (ACH4471) is a novel, selective and orally bioavailable small-molecule factor D inhibitor, which inhibits alternative pathway of complement (APC) activity. It shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Danicopan has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

纯度：≥98%

CAS：1903768-17-1